Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Hepatitis C vaccine"'
Autor:
Makutiro Ghislain Masavuli, Danushka K. Wijesundara, Alexander Underwood, Dale Christiansen, Linda Earnest-Silveira, Rowena Bull, Joseph Torresi, Eric J. Gowans, Branka Grubor-Bauk
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Hepatitis C virus (HCV) persistently infects approximately 71 million people globally. To prevent infection a vaccine which elicits neutralizing antibodies against the virus envelope proteins (E1/E2) which are required for entry into host cells is de
Externí odkaz:
https://doaj.org/article/32b789aba05b4e2d8afac24bdc052744
Autor:
Elodie Beaumont, Philippe Roingeard
Publikováno v:
Hepatology. 71:1845-1850
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e16eef9bb0683f85d8b26cfda5ed4e65
https://doi.org/10.1002/hep.31182
https://doi.org/10.1002/hep.31182
Autor:
Manal Elsayed, Eleanor Barnes, Margaret Hellard, Adele Schwartz Benzaken, Alexander J. Thompson, Heidi E. Drummer, Nick Scott, David Wilson
Publikováno v:
BMC Medicine, Vol 17, Iss 1, Pp 1-12 (2019)
BMC Medicine
BMC Medicine
Background The introduction of highly effective direct-acting antiviral (DAA) therapy for hepatitis C has led to calls to eliminate it as a public health threat through treatment-as-prevention. Recent studies suggest it is possible to develop a vacci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79ec3c9eea1b349c29e7834aa3e28ebc
http://link.springer.com/article/10.1186/s12916-019-1411-9
http://link.springer.com/article/10.1186/s12916-019-1411-9
Publikováno v:
Journal of Substance Abuse Treatment. 101:67-71
A major complicating factor for hepatitis C virus (HCV) vaccine clinical trial design and implementation is engagement and retention of people who use drugs (PWUD). Informed willingness to participate (WTP) in vaccine trials has emerged as a critical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dd10ffed7f7cb6a359b4dfda50ca066
https://doi.org/10.1016/j.jsat.2019.03.010
https://doi.org/10.1016/j.jsat.2019.03.010
Publikováno v:
Vaccines, Vol 9, Iss 114, p 114 (2021)
Vaccines
Vaccines
The impactful discovery and subsequent characterisation of hepatitis C virus (HCV), an RNA virus of the flavivirus family, led to the awarding of the 2020 Nobel Prize in Physiology or Medicine to Harvey J. Alter, Michael Houghton and Charles M. Rice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e02e497faff827b4fef399c80868b93e
https://www.mdpi.com/2076-393X/9/2/114
https://www.mdpi.com/2076-393X/9/2/114
Autor:
Jordan J. Feld, John W. Ward
Publikováno v:
Hepatology Communications
Hepatology Communications, Vol 5, Iss 6, Pp 911-922 (2021)
Hepatology Communications, Vol 5, Iss 6, Pp 911-922 (2021)
With a decade left to reach the ambitious goals for viral hepatitis elimination set out by the World Health Organization, many challenges remain. Despite the remarkable improvements in therapy for hepatitis C virus (HCV) infection, most people living
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a61e3c5a1f11f8094a0177371e083e54
https://pubmed.ncbi.nlm.nih.gov/34141979
https://pubmed.ncbi.nlm.nih.gov/34141979
Autor:
Alexander Underwood, Joseph Torresi, Makutiro Ghislain Masavuli, Branka Grubor-Bauk, Eric J. Gowans, Linda Earnest-Silveira, Dale Christiansen, Danushka K. Wijesundara, Rowena A. Bull
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 10 (2019)
Frontiers in Immunology, Vol 10 (2019)
Hepatitis C virus (HCV) persistently infects approximately 71 million people globally. To prevent infection a vaccine which elicits neutralizing antibodies against the virus envelope proteins (E1/E2) which are required for entry into host cells is de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8caad9cc140acce7c78f36726e3de83d
https://pubmed.ncbi.nlm.nih.gov/31178869
https://pubmed.ncbi.nlm.nih.gov/31178869
Autor:
Matthew McConnell, Joseph K. Lim
Publikováno v:
Clinical Liver Disease. 12:118-121
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c68004b6786d84fcfc62ddc905329b8a
https://doi.org/10.1002/cld.753
https://doi.org/10.1002/cld.753
Publikováno v:
Viruses, Vol 13, Iss 1351, p 1351 (2021)
Viruses
Viruses
Thirty years after its discovery, the hepatitis C virus (HCV) remains a leading cause of liver disease worldwide. Given that many countries continue to experience high rates of transmission despite the availability of potent antiviral therapies, an e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4fc5359e30ac5a3c8056d25895ee9f9
https://doi.org/10.3390/v13071351
https://doi.org/10.3390/v13071351
Publikováno v:
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 26(7)
Background Chronic hepatitis C virus (HCV) infection affects 71 million people worldwide. The availability of highly efficient direct-acting antivirals has revolutionized the treatment landscape with over 95% cure rates. The WHO has launched a global
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8627dec7dea92552ce026657428c3559
https://pubmed.ncbi.nlm.nih.gov/31978546
https://pubmed.ncbi.nlm.nih.gov/31978546